Sobi®
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com (http://www.sobi.com/), LinkedIn (https://www.linkedin.com/company/sobi/) and YouTube (https://www.youtube.com/c/Sobi-Pharma).
Contacts
For details on how to contact the Sobi Investor Relations Team, please clickhere (https://www.sobi.com/en/ir-contacts). For Sobi Media contacts, clickhere (https://www.globenewswire.com/Tracker?data=V0r-79xNQigPhVSPHaEkI7yQDPbL5AqXhpqEm-zyy2OxF3z2QvH-Lfy0_AqiqZqknvIdocO0HEjH0mmbybEG0g==).
This information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08:00 CEST on 30 September 2022.